Results 151 to 160 of about 22,494 (197)

Complete laparoscopic wedge resection of a giant locally advanced gastric GIST with near pathological complete response after preoperative treatment with imatinib mesylate: A case report. [PDF]

Int J Surg Case Rep, 2022
Guo H, Li Y, Wang D, Tan B, Yang P, Zhao Q.   +5 more
europepmc   +1 more source

QbD-based co-loading of paclitaxel and imatinib mesylate by protamine-coated PLGA nanoparticles effective on breast cancer cells. [PDF]

Nanomedicine (Lond)
Laxane N, Yadav KS.
europepmc   +1 more source

Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model. [PDF]

In Vivo, 2021
Pinto CA, DE Sousa Portilho AJ, Barbosa MC, DE Moraes MEA, DE Lemos JAR, Burbano RMR, Moreira-Nunes CA.   +6 more
europepmc   +1 more source

MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate. [PDF]

Int J Mol Sci, 2021
Martins JRB, Moraes LN, Cury SS, Capannacci J, Carvalho RF, Nogueira CR, Hokama NK, Hokama POM.   +7 more
europepmc   +1 more source

Use of a pH-responsive imatinib mesylate sustained-release hydrogel for the treatment of tendon adhesion by inhibiting PDGFRβ/CLDN1 pathway. [PDF]

Bioact Mater
Pang S, Wu R, Lv W, Zou J, Li Y, Li Y, Zhang P, Ma X, Wang Y, Liu S.   +9 more
europepmc   +1 more source

Safety outcomes of low versus high dose imatinib mesylate in patients with advanced, metastatic, or nonresectable gastrointestinal stromal tumors: A systematic review. [PDF]

Gastrointest Tract
Marucci MA, Lechner DW, Tafuto BA.
europepmc   +1 more source

A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients. [PDF]

PLoS One
Zeng L, Cheng X, Li J, Zhang J, Wu X.
europepmc   +1 more source

Imatinib as a novel therapeutic approach for fibrotic disorders [PDF]

, 2017
Distler, J. H. W., Distler, O.
core  

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors [PDF]

, 2010
Robert S. Benjamin, Patrick Schöffski, Jörg Thomas Hartmann, Allan Van Oosterom, Binh Nguyen Bui, Justus Duyster, Scott Schuetze, Jean-Yves Blay, Peter Reichardt, Lee S. Rosen, Keith Skubitz, Sheryl McCoy, Yu-Nien Sun, Daniel E. Stepan, Laurence Baker   +14 more
core   +1 more source

Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance. [PDF]

Cancers (Basel)
Boichuk S, Dunaev P, Galembikova A, Valeeva E.   +3 more
europepmc   +1 more source